EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 6-Nov-2025 19:11 ET (7-Nov-2025 00:11 GMT/UTC)

AI-informed approach to CAR design enhances bi-specific CAR T cells

St. Jude Children's Research Hospital
Peer-Reviewed Publication

Chimeric antigen receptor (CAR) T–cell immunotherapy reprograms a patient’s immune cells to target a cancer-specific cell surface protein. CAR T cells have been effective against blood cancers, but do not work as well in solid and brain tumors because cancer cells do not uniformly express the same cell surface proteins, allowing cancer cells to escape treatment and regrow the tumor.

Journal: Molecular Therapy
Funder: NIH/National Cancer Institute, NIH/National Cancer Institute, NIH/National Institute of Neurological Disorders and Stroke

Oncology, primary care coordination necessary for best cancer patient outcomes

University of Missouri-Columbia
Peer-Reviewed Publication

The need for proper cancer survivorship care grows with each new case of remission, but according to new research from the University of Missouri School of Medicine, primary care could fill that need, given enough support.

Journal: Current Oncology

Counties with low rates of cervical cancer screening see higher rates of incidence and death

Medical University of South Carolina
Peer-Reviewed Publication

Women in counties with repeatedly lower cervical cancer screening rates suffer nearly double the rate of cervical cancer diagnoses, particularly of late-stage disease, and death from cervical cancer, according to a new analysis from researchers at MUSC Hollings Cancer Center.

Journal: JAMA Network Open
Funder: Hollings Cancer Center, NIH/National Cancer Institute, NIH/National Cancer Institute

County-level cervical cancer screening coverage and differences in incidence and mortality

JAMA Network
Peer-Reviewed Publication

This study found a nearly two-fold higher cervical cancer incidence, late-stage diagnosis, and mortality in counties with repeatedly low vs high cervical cancer screening coverage. Most counties with repeat low coverage were rural and lower income.

Journal: JAMA Network Open

Gauging the magnitude of missed opportunity for ovarian cancer prevention

JAMA Network
Peer-Reviewed Publication

In this study, a considerable proportion of patients with high-grade serous cancer missed opportunities for risk assessment with genetic testing and for surgical prevention. Given the lack of effective screening and limited treatment options for high-grade serous cancer, eradicating it requires addressing the full spectrum of missed opportunities.

Journal: JAMA Surgery

NRG Oncology appoints new NCORP and Veteran Affairs Research Leadership

NRG Oncology
Business Announcement

NRG Oncology (NRG), a National Cancer Institute (NCI) National Clinical Trials Network (NCTN) group focused on improving outcomes for adults with cancer through multi-center clinical research, recently announced new Deputy NRG National Cancer Institute (NCI) Community Oncology Research Program (NCORP) Chair and Vice Chair of the NRG Veteran Affairs & Military Treatment Facility (VA-MTF) Subcommittee.

A progressive evolution in virtual MRI imaging for tumor detection

The Hong Kong Polytechnic University
Peer-Reviewed Publication

During magnetic resonance imaging (MRI) procedures, contrast agents, such as the rare metal gadolinium, can pose potential health risks. Researchers at The Hong Kong Polytechnic University (PolyU) have spent years developing contrast-free scanning technology and successfully developed AI-powered virtual MRI imaging for accurate turmour detection, offering a safer and smarter diagnostic approach.

Journal: International Journal of Radiation Oncology*Biology*Physics

New treatment eliminates bladder cancer in 82% of patients

University of Southern California - Health Sciences
Peer-Reviewed Publication

A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously resisted treatment.

Journal: Journal of Clinical Oncology

New compound disrupts survival pathways in aromatase inhibitor-resistant breast cancer cells

Impact Journals LLC
Peer-Reviewed Publication

BUFFALO, NY – August 13, 2025 – A new research paper was published in Volume 16 of Oncotarget on July 29, 2025, titled “PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase inhibitor-resistant breast cancer cells while disrupting actin filaments and focal adhesion.”

Journal: Oncotarget

Dual immune checkpoint inhibition with radiotherapy does not improve progression-free survival for patients with newly diagnosed MGMT-unmethylated glioblastoma

NRG Oncology
Peer-Reviewed Publication

NRG Oncology recently reported the results of the National Cancer Institute sponsored phase II/III NRG-BN007 clinical trial showing that combining ipilimumab and nivolumab with radiation therapy (RT) did not improve progression-free survival (PFS) for patients with newly diagnosed MGMT-unmethylated (uMGMT) glioblastoma in comparison to standard RT with temozolomide (TMZ).

Journal: Journal of Clinical Oncology

93
94
95
96
97